臨床試驗

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT：NCT06831136 · RECRUITING

NCT IDNCT06831136

狀態RECRUITING

開始日期2025-03-26

完成時間2030-01-20

SponsorThe University of Texas Health Science Center, Houston (OTHER)

First posted2025-02-17

Last updated2026-10-08

簡要摘要

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。